Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. April 2019 07:05 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Present New Data from Ongoing Studies of Tumor-Infiltrating Lymphocyte (TIL) Therapy at 2019 American Society of Clinical Oncology (ASCO) Meeting

SAN CARLOS, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on...
03. April 2019 07:00 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Announces Clinical Programs Update

- Design of cervical cancer study amended in anticipation for regulatory interactions - - Global IOV-COM-202 study to add new combination arm for patients with non-small cell lung...
02. April 2019 07:00 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma

- Patient dosing commenced in pivotal metastatic melanoma cohort - - Submission for regulatory approval of lifileucel is on target for late 2020 - SAN CARLOS, Calif., April 02, 2019 (GLOBE...
01. April 2019 08:00 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Presents Data at AACR Annual Meeting on T-Cell Diversity and Persistence in Patients Receiving Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel

- Data from cohort 2 of the innovaTIL-01 study support polyclonal approach necessary to treat metastatic melanoma - SAN CARLOS, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics,...
29. März 2019 08:23 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Announces April Scientific and Investor Presentations

SAN CARLOS, Calif., March 29, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on...
06. März 2019 07:00 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Present at Upcoming Investor Conferences in March

SAN CARLOS, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
27. Februar 2019 16:01 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update

- Patient Enrollment Commenced in the Registrational Cohort 4 in Study of Lifileucel in Advanced Melanoma - - FDA Granted Fast Track Designation for LN-145 for Treatment of Patients with Recurrent,...
22. Februar 2019 07:00 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call and Webcast on Wednesday, February 27, 2019

SAN CARLOS, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
01. Februar 2019 07:00 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences

SAN CARLOS, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
21. Dezember 2018 07:00 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

SAN CARLOS, Calif., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...